Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial

摘要: Purpose Use of adjuvant radiation therapy (RT) after neoadjuvant chemotherapy (NAC) in node-positive breast cancer (BC) is highly variable. In ACOSOG Z1071, RT NAC was used at the discretion treating physicians. Herein, we report impact and pathologic response on locoregional recurrence (LRR) NAC. Methods Materials Z1071 enrolled women with cT0-4N1-2 BC treated from 2009 to 2011. Patients underwent sentinel node surgery completion axillary lymph dissection. The Patient outcomes were analyzed as a function clinical-pathologic factors use RT. Results Of 701 eligible patients, mastectomy performed 423 (59.6%) breast-conserving 277 (40.4%). After NAC, residual disease observed 506 (72.2%), 195 (27.8%) had complete response. 591 (85.3%) received 102 (14.7%) did not. Median follow-up 5.9 years. Forty-three patients (6.1%) experienced LRR, 145 (20.7%) distant metastasis, 142 (20.4%) died. best LRR-relapse-free survival (hazard ratio [HR], 0.32; 95% confidence interval, 0.12-0.81; P = .016), metastasis–free (HR, 0.31; CI, 0.19-0.52; Conclusion trial, which physicians, associated trend toward decreased LRR. There no association overall survival, BC-specific survival, or Disease Specific Survival. Triple-negative higher relapse rates.